{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:34:29Z","timestamp":1793237669878,"version":"4.5.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:00:00Z","timestamp":1774051200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["BC230508"],"award-info":[{"award-number":["BC230508"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["BC191055"],"award-info":[{"award-number":["BC191055"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["1 R01 CA238217-01A1"],"award-info":[{"award-number":["1 R01 CA238217-01A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ymthe.2026.03.026","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T19:00:17Z","timestamp":1774465217000},"page":"4121-4135","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Enhanced efficacy of a next-generation EEEV self-replicating RNA platform for combination cancer immunotherapies"],"prefix":"10.1016","volume":"34","author":[{"given":"Shigeki J.","family":"Miyake-Stoner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian J.","family":"Maine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie C.","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle P.","family":"Dailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darina S.","family":"Spasova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine C.","family":"Domingo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Sparks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaelle","family":"Picarda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Kim","family":"Lyerly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika J.","family":"Crosby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Geall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel S.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary C.","family":"Hartman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2655-2829","authenticated-orcid":false,"given":"Parinaz","family":"Aliahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2026.03.026_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology Meets Immunology: The Cancer-Immunity Cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2026.03.026_bib2","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12943-025-02305-x","article-title":"Advances in cancer immunotherapy: historical perspectives, current developments, and future directions","volume":"24","author":"Zhang","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ymthe.2026.03.026_bib3","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1158\/2326-6066.CIR-13-0220","article-title":"Combination of Alphavirus replicon particle-based vaccination with immunomodulatory antibodies: therapeutic activity in the B16 melanoma mouse model and immune correlates","volume":"2","author":"Avogadri","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ymthe.2026.03.026_bib4","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA Vaccine against SARS-CoV-2 \u2014 Preliminary Report","volume":"383","author":"Jackson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.03.026_bib5","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","article-title":"Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults","volume":"586","author":"Mulligan","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.03.026_bib6","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.03.026_bib7","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.03.026_bib8","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1038\/s41591-024-02955-2","article-title":"An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2\/3 randomized trial","volume":"30","author":"Saraf","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.03.026_bib9","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S1473-3099(23)00650-3","article-title":"Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial","volume":"24","author":"Oda","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ymthe.2026.03.026_bib10","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.4049\/jimmunol.1601877","article-title":"Induction of an IFN-Mediated Antiviral Response by a Self-Amplifying RNA Vaccine: Implications for Vaccine Design","volume":"198","author":"Pepini","year":"2017","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2026.03.026_bib11","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1006\/viro.1997.8878","article-title":"Replicon-Helper Systems from Attenuated Venezuelan Equine Encephalitis Virus: Expression of Heterologous Genesin Vitroand Immunization against Heterologous Pathogensin Vivo","volume":"239","author":"Pushko","year":"1997","journal-title":"Virology"},{"key":"10.1016\/j.ymthe.2026.03.026_bib12","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/s41417-022-00435-8","article-title":"Next generation self-replicating RNA vectors for vaccines and immunotherapies","volume":"30","author":"Aliahmad","year":"2023","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ymthe.2026.03.026_bib13","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/s41467-025-55843-9","article-title":"Safety and immunogenicity of an optimized self-replicating RNA platform for low dose or single dose vaccine applications: a randomized, open label Phase I study in healthy volunteers","volume":"16","author":"Maine","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.03.026_bib14","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s43856-025-01147-4","article-title":"Durability of next-generation self-replicating RNA vaccine RBI-4000: a phase 1, randomized open label clinical trial","volume":"5","author":"Maine","year":"2025","journal-title":"Commun. Med."},{"key":"10.1016\/j.ymthe.2026.03.026_bib15","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1016\/j.ymthe.2021.04.001","article-title":"A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice","volume":"29","author":"de Alwis","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.03.026_bib16","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.03.026_bib17","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40425-019-0520-5","article-title":"Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer","volume":"7","author":"Papachristofilou","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2026.03.026_bib18","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.03.026_bib19","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.03.026_bib20","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"The Lancet"},{"key":"10.1016\/j.ymthe.2026.03.026_bib21","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1038\/s41591-022-01937-6","article-title":"Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results","volume":"28","author":"Palmer","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.03.026_bib22","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/s41417-023-00587-1","article-title":"Clinical trials of self-replicating RNA-based cancer vaccines","volume":"30","author":"Morse","year":"2023","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ymthe.2026.03.026_bib23","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat9143","article-title":"Durable anticancer immunity from intratumoral administration of IL-23, IL-36\u03b3, and OX40L mRNAs","volume":"11","author":"Hewitt","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2026.03.026_bib24","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc7804","article-title":"Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models","volume":"13","author":"Hotz","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2026.03.026_bib25","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ymthe.2017.11.017","article-title":"Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses","volume":"26","author":"Vogel","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.03.026_bib26","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1016\/j.ymthe.2023.07.006","article-title":"LION: Taming RNA vaccine inflammation","volume":"31","author":"Tregoning","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.03.026_bib27","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13058-020-1246-5","article-title":"ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis","volume":"22","author":"Zundelevich","year":"2020","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ymthe.2026.03.026_bib28","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13058-020-01290-x","article-title":"Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer","volume":"22","author":"Clatot","year":"2020","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ymthe.2026.03.026_bib29","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/annonc\/mdx483","article-title":"Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer","volume":"29","author":"Fribbens","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ymthe.2026.03.026_bib30","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.2147\/CMAR.S173193","article-title":"Clinical value of circulating ESR1 mutations for patients with metastatic breast cancer: a meta-analysis","volume":"10","author":"Zhang","year":"2018","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.ymthe.2026.03.026_bib31","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/ng.2822","article-title":"ESR1 ligand-binding domain mutations in hormone-resistant breast cancer","volume":"45","author":"Toy","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2026.03.026_bib32","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13058-021-01462-3","article-title":"ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer","volume":"23","author":"Brett","year":"2021","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ymthe.2026.03.026_bib33","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqab153","article-title":"HER2 Activation and Endocrine Treatment Resistance in HER2-negative Breast Cancer","volume":"162","author":"Mazumder","year":"2021","journal-title":"Endocrinology"},{"key":"10.1016\/j.ymthe.2026.03.026_bib34","article-title":"HER3 signaling and targeted therapy in cancer","volume":"12","author":"Mishra","year":"2018","journal-title":"Oncol. Rev."},{"key":"10.1016\/j.ymthe.2026.03.026_bib35","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.1200\/JCO.2010.34.4879","article-title":"Phosphatidylinositol 3-Kinase and Antiestrogen Resistance in Breast Cancer","volume":"29","author":"Miller","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2026.03.026_bib36","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumors","volume":"490","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.03.026_bib37","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-62664-1","article-title":"PIK3CA mutations in endocrine-resistant breast cancer","volume":"14","author":"Schagerholm","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2026.03.026_bib38","doi-asserted-by":"crossref","first-page":"5670","DOI":"10.1158\/1078-0432.CCR-04-0110","article-title":"HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study","volume":"10","author":"Arpino","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2026.03.026_bib39","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s10549-023-07038-3","article-title":"Frequent upregulation of HER2 protein in hormone-receptor-positive HER2-negative breast cancer after short-term neoadjuvant endocrine therapy","volume":"201","author":"Chaudhary","year":"2023","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ymthe.2026.03.026_bib40","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2309693","article-title":"Vaccines targeting ESR1 activating mutations elicit anti-tumor immune responses and suppress estrogen signaling in therapy resistant ER+ breast cancer","volume":"20","author":"Dailey","year":"2024","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.ymthe.2026.03.026_bib41","doi-asserted-by":"crossref","first-page":"4670","DOI":"10.1158\/1078-0432.CCR-20-0389","article-title":"Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and \u03b1PD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer","volume":"26","author":"Crosby","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2026.03.026_bib42","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1158\/1078-0432.CCR-18-3102","article-title":"Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study","volume":"25","author":"Crosby","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2026.03.026_bib43","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1315495","article-title":"Vaccination targeting human HER3 alters the phenotype of infiltrating T cells and responses to immune checkpoint inhibition","volume":"6","author":"Osada","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ymthe.2026.03.026_bib44","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000258","article-title":"HER2-LAMP vaccines effectively traffic to endolysosomal compartments and generate enhanced polyfunctional T cell responses that induce complete tumor regression","volume":"8","author":"Chen","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2026.03.026_bib45","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1158\/1078-0432.CCR-09-2549","article-title":"An Adenoviral Vaccine Encoding Full-Length Inactivated Human HER2 Exhibits Potent Immunogenicty and Enhanced Therapeutic Efficacy Without Oncogenicity","volume":"16","author":"Hartman","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2026.03.026_bib46","first-page":"409","article-title":"Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies","volume":"3","author":"Atkins","year":"1997","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2026.03.026_bib47","doi-asserted-by":"crossref","first-page":"8835","DOI":"10.1200\/JCO.2005.02.1691","article-title":"Phase I study of the sequential combination of interleukin-12 and interferon alfa-2b in advanced cancer: evidence for modulation of interferon signaling pathways by interleukin-12","volume":"23","author":"Eisenbeis","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2026.03.026_bib48","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1158\/1078-0432.CCR-20-3944","article-title":"Intratumoral plasmid IL12 expands CD8+ T Cells and induces a CXCR3 gene signature in triple-negative breast tumors that sensitizes patients to anti-PD-1 therapy","volume":"27","author":"Telli","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2026.03.026_bib49","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1158\/1078-0432.CCR-18-1512","article-title":"First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors","volume":"25","author":"Strauss","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2026.03.026_bib50","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1073\/pnas.88.9.3681","article-title":"cDNA cloning of an intracellular form of the human interleukin 1 receptor antagonist associated with epithelium","volume":"88","author":"Haskill","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.03.026_bib51","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.3389\/fphar.2018.01157","article-title":"Anakinra Therapy for Non-cancer Inflammatory Diseases","volume":"9","author":"Cavalli","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ymthe.2026.03.026_bib52","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/S0140-6736(17)32247-X","article-title":"Effect of interleukin-1\u03b2 inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Ridker","year":"2017","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.ymthe.2026.03.026_bib53","doi-asserted-by":"crossref","first-page":"114","DOI":"10.4065\/84.2.114","article-title":"Induction of a Chronic Disease State in Patients With Smoldering or Indolent Multiple Myeloma by Targeting Interleukin 1\u03b2-Induced Interleukin 6 Production and the Myeloma Proliferative Component","volume":"84","author":"Lust","year":"2009","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.ymthe.2026.03.026_bib54","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3389\/fphys.2014.00114","article-title":"The role IL-1 in tumor-mediated angiogenesis","volume":"5","author":"Voronov","year":"2014","journal-title":"Front. Physiol."},{"key":"10.1016\/j.ymthe.2026.03.026_bib55","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3390\/cancers12020433","article-title":"The IL-1 Antagonist Anakinra Attenuates Glioblastoma Aggressiveness by Dampening Tumor-Associated Inflammation","volume":"12","author":"H\u00fcbner","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ymthe.2026.03.026_bib56","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.ymthe.2020.11.027","article-title":"Self-Replicating RNAs Drive Protective Anti-tumor T Cell Responses to Neoantigen Vaccine Targets in a Combinatorial Approach","volume":"29","author":"Maine","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.03.026_bib57","doi-asserted-by":"crossref","unstructured":"Spasova, D.S., Miyake-Stoner, S.J., Picarda, G., Chou, A.C., Brand, E.D., Olesiuk, M.D., Domingo, C.C., Little, H.J., Goodman, T.T., Posy, J.L., et al. (2025). Novel srRNA Vectors for Customizable Vaccine Development. Vaccine Insights.4,55-62, DOI: 10.18609\/vac.2025.008.","DOI":"10.18609\/vac.2025.008"},{"key":"10.1016\/j.ymthe.2026.03.026_bib58","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202508907","article-title":"Divergent Delivery and Expression Kinetics of Lipid and Polymeric Nanoparticles across mRNA Modalities","volume":"12","author":"Casmil","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ymthe.2026.03.026_bib59","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01865-22","article-title":"All Domains of SARS-CoV-2 nsp1 Determine Translational Shutoff and Cytotoxicity of the Protein","volume":"97","author":"Frolov","year":"2023","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2026.03.026_bib60","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.ymthe.2024.12.055","article-title":"Alphaviral backbone of self-amplifying RNA enhances protein expression and immunogenicity against SARS-CoV-2 antigen","volume":"33","author":"Casmil","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.03.026_bib61","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature18300","article-title":"Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy","volume":"534","author":"Kranz","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.03.026_bib62","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nature14426","article-title":"Mutant MHC class II epitopes drive therapeutic immune responses to cancer","volume":"520","author":"Kreiter","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.03.026_bib63","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1084\/jem.170.3.827","article-title":"Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes","volume":"170","author":"Kobayashi","year":"1989","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymthe.2026.03.026_bib64","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1084\/jem.178.4.1223","article-title":"Antitumor and antimetastatic activity of interleukin 12 against murine tumors","volume":"178","author":"Brunda","year":"1993","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymthe.2026.03.026_bib65","first-page":"1661","article-title":"Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma","volume":"3","author":"Teicher","year":"1997","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2026.03.026_bib66","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/(SICI)1097-0215(19960103)65:1<80::AID-IJC14>3.0.CO;2-M","article-title":"In vivo studies with interleukin-12 alone and in combination with monocyte colony-stimulating factor and\/or fractionated radiation treatment","volume":"65","author":"Teicher","year":"1996","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ymthe.2026.03.026_bib67","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1038\/s43018-020-0095-6","article-title":"Multifunctional oncolytic nanoparticles deliver self-replicating IL-12 RNA to eliminate established tumors and prime systemic immunity","volume":"1","author":"Li","year":"2020","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.ymthe.2026.03.026_bib68","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.omtn.2022.07.020","article-title":"Intratumoral electroporation of a self-amplifying RNA expressing IL-12 induces antitumor effects in mouse models of cancer","volume":"29","author":"Silva-Pilipich","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2026.03.026_bib69","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","article-title":"Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade","volume":"170","author":"Wei","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2026.03.026_bib70","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12864-019-6344-3","article-title":"Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumors","volume":"21","author":"Zhong","year":"2020","journal-title":"BMC Genomics"},{"key":"10.1016\/j.ymthe.2026.03.026_bib71","first-page":"5","article-title":"CTLA-4 blockade in tumor models: an overview of preclinical and translational research","volume":"13","author":"Grosso","year":"2013","journal-title":"Cancer Immun."},{"key":"10.1016\/j.ymthe.2026.03.026_bib72","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1073\/pnas.1812266115","article-title":"Blocking IL-1\u03b2 reverses the immunosuppression in mouse breast cancer and synergizes with anti-PD-1 for tumor abrogation","volume":"116","author":"Kaplanov","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.03.026_bib73","article-title":"Targeting inflammasome\/IL-1 pathways for cancer immunotherapy","volume":"6","author":"Guo","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2026.03.026_bib74","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1158\/1078-0432.CCR-15-1823","article-title":"Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1\u03b2, IL8, CXCL5, and Mip-1\u03b1","volume":"23","author":"Najjar","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2026.03.026_bib75","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.1038\/s41467-023-39053-9","article-title":"GRT-R910: a self-amplifying mRNA SARS-CoV-2 vaccine boosts immunity for \u22656 months in previously-vaccinated older adults","volume":"14","author":"Palmer","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.03.026_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101262","article-title":"Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial","volume":"44","author":"Pollock","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ymthe.2026.03.026_bib77","first-page":"147","article-title":"Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki forest virus vector carrying the human interleukin-12 gene--a phase I\/II clinical protocol","volume":"64","author":"Ren","year":"2003","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.ymthe.2026.03.026_bib78","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0259301","article-title":"Intratumoral expression of IL-12 from lentiviral or RNA vectors acts synergistically with TLR4 agonist (GLA) to generate anti-tumor immunological memory","volume":"16","author":"Leleux","year":"2021","journal-title":"PLOS ONE"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626002121?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626002121?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:23:29Z","timestamp":1793237009000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001626002121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":78,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1525001626002121"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.03.026","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhanced efficacy of a next-generation EEEV self-replicating RNA platform for combination cancer immunotherapies","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.03.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}